

Version 2.4 Revision Date: 09.04.2021 SDS Number: 402660-00012 Date of last issue: 10.10.2020
Date of first issue: 07.01.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Olmesartan / Amlodipine Besylate Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.
30 Hudson Street, 33rd floor
07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person
responsible for the SDS : EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2	H319: Causes serious eye irritation.
Reproductive toxicity, Category 1A	H360D: May damage the unborn child.
Long-term (chronic) aquatic hazard, Category 3	H412: Harmful to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :  

Signal word : Danger

Hazard statements : H319 Causes serious eye irritation.
H360D May damage the unborn child.
H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.

Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

P337 + P313 If eye irritation persists: Get medical advice/ attention.

Hazardous components which must be listed on the label:

Olmesartan

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Olmesartan	144689-63-4	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 1A; H360D	>= 10 - < 20
Amlodipine Besylate	652969-01-2	Acute Tox. 4; H302 Eye Irrit. 2; H319 Aquatic Chronic 2; H411	>= 2,5 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures**4.1 Description of first aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.

Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016

- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : Causes serious eye irritation.
May damage the unborn child.
- Contact with dust can cause mechanical irritation or drying of the skin.

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.
-

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

- Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

- Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage**7.1 Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.

Olmesartan / Amlodipine Besylate Formulation

Version 2.4 Revision Date: 09.04.2021 SDS Number: 402660-00012 Date of last issue: 10.10.2020
Date of first issue: 07.01.2016

Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection**8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	TWA OEL-RL (Respirable dust)	5 mg/m ³	ZA OEL
Further information: Recommended Limit				
		TWA OEL-RL (inhalable dust)	10 mg/m ³	ZA OEL
Further information: Recommended Limit				
		STEL OEL-RL (Dust)	20 mg/m ³	ZA OEL
Further information: Recommended Limit				

Olmesartan / Amlodipine Besylate Formulation

Version 2.4 Revision Date: 09.04.2021 SDS Number: 402660-00012 Date of last issue: 10.10.2020
Date of first issue: 07.01.2016

Olmesartan	144689-63-4	TWA	30 µg/m ³ (OEB 3)	Internal
		Wipe limit	300 µg/100 cm ²	Internal
Amlodipine Besylate	652969-01-2	TWA	20 µg/m ³ (OEB 3)	Internal
		Wipe limit	100 µg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

- Appearance : powder
- Colour : No data available
- Odour : No data available
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available

Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016

Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids)	:	No data available
Particle size	:	No data available

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
---------------------	---	--

Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:**Olmesartan:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
LD50 (Mouse): > 2.000 mg/kg
LD50 (Dog): > 1.500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Amlodipine Besylate:

Acute oral toxicity : LD50 (Rat): 393 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**Olmesartan:**

Remarks : No data available

Serious eye damage/eye irritation

Causes serious eye irritation.

Olmesartan / Amlodipine Besylate Formulation

Version 2.4 Revision Date: 09.04.2021 SDS Number: 402660-00012 Date of last issue: 10.10.2020
Date of first issue: 07.01.2016

Components:**Olmesartan:**

Species : Rabbit
Method : Draize Test
Result : Moderate eye irritation

Amlodipine Besylate:

Species : Rabbit
Result : Severe irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Olmesartan:**

Exposure routes : Skin contact
Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:**Olmesartan:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Mutagenicity (in vitro mammalian cytogenetic test)
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster lung cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Amlodipine Besylate:

Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Olmesartan:**

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 6 Months
Result : negative

Amlodipine Besylate:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Reproductive toxicity

May damage the unborn child.

Components:**Olmesartan:**

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 1.000 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Development
Species: Rat
Application Route: Oral
Dose: 1000 milligram per kilogram
Result: No teratogenic effects

Test Type: Development
Species: Rabbit
Application Route: Oral

Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016

Dose: 1 milligram per kilogram

Result: No teratogenic effects

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: \geq 1,6 mg/kg body weight

Symptoms: Malformations were observed., Reduced body weight

Result: Effects on postnatal development

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.

Amlodipine Besylate:

Effects on fertility

: Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Fertility: NOAEL: 10 mg/kg body weight

Result: No effects on fertility

Test Type: Fertility/early embryonic development

Species: Rabbit

Application Route: Ingestion

Fertility: NOAEL: 25 mg/kg body weight

Result: No effects on fertility

Effects on foetal development

: Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Developmental Toxicity: LOAEL: 10 mg/kg body weight

Result: Effects on foetal development

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Ingestion

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: No effects on foetal development

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Ingestion

Developmental Toxicity: LOAEL: 1,6 mg/kg body weight

Result: Effects on foetal development

Remarks: Maternal toxicity observed.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016

Repeated dose toxicity**Components:****Olmesartan:**

Species	:	Rat
NOAEL	:	2.000 mg/kg
Application Route	:	Oral
Exposure time	:	24 Months
Remarks	:	No significant adverse effects were reported

Amlodipine Besylate:

Species	:	Rat
NOAEL	:	15 mg/kg
Application Route	:	Oral
Exposure time	:	90 d
Remarks	:	No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Product:**

Ingestion	:	Symptoms: Fatigue, Dizziness, Headache, Nausea
-----------	---	--

Components:**Olmesartan:**

Eye contact	:	Symptoms: Eye irritation
Ingestion	:	Symptoms: hypotension
		Remarks: May cause harm to the unborn child.
		Based on Human Evidence

Amlodipine Besylate:

Eye contact	:	Symptoms: Severe irritation
Ingestion	:	Symptoms: Nausea, Abdominal pain, Fatigue, Headache, Oedema, Palpitation

SECTION 12: Ecological information**12.1 Toxicity****Components:****Amlodipine Besylate:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 2,7 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 3,2 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	IC50 (Pseudokirchneriella subcapitata (green algae)): 5,6 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential**Components:****Amlodipine Besylate:**Partition coefficient: n- : log Pow: 3
octanol/water**12.4 Mobility in soil**

No data available

12.5 Results of PBT and vPvB assessment**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects**Product:**Endocrine disrupting poten- : The substance/mixture does not contain components consid-
tial : ered to have endocrine disrupting properties according to
REACH Article 57(f) or Commission Delegated regulation
(EU) 2017/2100 or Commission Regulation (EU) 2018/605 at
levels of 0.1% or higher.

SECTION 13: Disposal considerations**13.1 Waste treatment methods**Product : Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes
are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in
discussion with the waste disposal authorities.
Contaminated packaging : Empty containers should be taken to an approved waste han-
dling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information**14.1 UN number**

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H319 : Causes serious eye irritation.

H360D : May damage the unborn child.

H411 : Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

ZA OEL : South Africa. Hazardous Chemical Substances Regulations, Occupational Exposure Limits

ZA OEL / TWA OEL-RL : Long term occupational exposure limits - recommended limit

ZA OEL / STEL OEL-RL : Short term occupational exposure limits - recommended limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous

Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016

Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Eye Irrit. 2	H319
Repr. 1A	H360D
Aquatic Chronic 3	H412

Classification procedure:

Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.4	09.04.2021	402660-00012	Date of first issue: 07.01.2016
